|
Aspen Pharmacare Holdings Limited - Aspen awarded lion`s share of ARV tender
Aspen Pharmacare Holdings Limited
(Incorporated in the Republic of South Africa)
(Registration number 1985/002935/06)
Share code: APN ISIN: ZAE000023586
Press Release
Friday, March 4, 2005
Aspen awarded lion`s share of ARV tender
JSE Securities Exchange listed Aspen Pharmacare, Africa`s largest pharmaceutical
manufacturer, has been awarded the lion`s share of the SA Government`s multi-
million rand anti-retroviral (ARV) tender for the treatment of HIV/Aids.
Stephen Saad, Aspen Group CEO said `we are really pleased with the announcement
and specifically as Aspen, a local pharmaceutical manufacturer of world-class
generic ARVs, has been selected to produce the bulk of the medicines needed to
treat millions of South Africans inflicted with HIV/Aids. Our R200 million Oral
Solid Dosage (OSD) facility based in Port Elizabeth was specifically established
to provide additional capacity for the increased demand for generic medicines
and ARVs in South Africa as well as other offshore regulated markets.`
The percentage of the tender awarded to Aspen for products tendered is as
follows:
Aspen
Department of Health
ARV Tender Awarded March 3, 2005
Product & Dosage % Awarded to
Aspen
Didanosine 25mg, 50mg and 60mg 100%
Nevirapine 200mg - 60`s 100%
Zidovudine 300mg - 60`s 100%
Zidovudine Syrup 50mg/5ml 200ml 100%
Lamivudine 10mg/ml 240ml 100%
Lamivudine 150mg - 60`s 80%
Stavudine 20mg - 60`s 100%
Stavudine 30mg - 60`s 70%
Stavudine 40mg - 60`s 60%
The ARV tablets and capsules will be produced at Aspen`s OSD facility, which was
recently acknowledged by the US Food and Drug Administration (FDA) as being the
world`s first generics manufacturing facility to receive FDA tentative approval
for the supply of generic triple combination ARV therapy to the US$15 billion
President`s Emergency Plan for AIDS Relief (PEPFAR) programme. The approval is
classified as `tentative` as there are still patents over the originator
products in the USA.
In 2004 Aspen was selected as one of only three ARV manufacturers worldwide to
be initially recognised by the Clinton Foundation initiative for combating
HIV/AIDS. This international recognition endorses Aspen`s world class
development and production capabilities.
Aspen pioneered the formulation and development of generic ARVs under voluntary
licences from the originators and subsequently launched Aspen-Stavudine -
Africa`s first generic ARV is August 2003. Aspen`s ARV basket is presently
comprised of Aspen Stavudine, Aspen Didanosine, Aspen Nevirapine, Aspen
Lamivudine (Tablets and Solution), Aspen Zidovudine (Tablets and Solution) and
Aspen Lamzid (combination Lamivudine/Zidovudine).
Aspen is Africa`s largest generics manufacturer and a major supplier of branded
pharmaceutical and healthcare products to African and selected international
markets. Aspen`s extensive basket of quality, effective and affordable products
is comprised of original, generic, over-the-counter (OTC), personal care, fast
moving consumer goods (FMCG), nutriceutical and nutritional brands.
ends
Issued by: Shauneen Beukes, Shauneen Beukes Communications
Tel: (012) 661-8467
Fax: (088) (012) 6618467
Cell: 082 389 8900
On Behalf Of: Stephen Saad, Aspen Pharmacare Group Chief Executive
Tel: (031) 580-8603
Fax: (031) 580-8640
Cell: 083 303 4833
Date: 04/03/2005 12:16:03 PM
Produced by the JSE SENS Department
| Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information. | |||||||||||||
| Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site | |||||||||||||
| [ Terms of Use | Privacy Policy | PAIA manual | FAQs/Help | Site Map | © Copyright Reserved 2026 ] | |||||||||||||
|
|||||||||||||
